N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

1 DEFINITY ® (Package Insert), North Billerica, MA, Lantheus Medical Imaging, Inc., 2017. 2 Parker JM, et al, Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.

Wilmington, DE -DuPont Pharmaceuticals announced today they have received FDA approval for their Definity? (Perflutren Lipid Microsphere) ultrasound contrast agent. Definity is used to improve the ...

Please provide your email address to receive an email when new articles are posted on . Lantheus Medical Imaging Inc. announced that the FDA has approved a label update that removes the ...

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc ...

JB Chemical & Pharmaceutical recently launched Definity vial, an ultrasound contrast imaging product in India under an exclusive multi-year marketing arrangement with Lantheus Medical Imaging.

In a comparison of patient outcomes after two stress imaging approaches, stress real-time myocardial contrast echocardiography improved the detection of CAD during stress echocardiography over ...

NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...